دورية أكاديمية
Antiproliferatives and Transplantation.
| العنوان: | Antiproliferatives and Transplantation. |
|---|---|
| المؤلفون: | Donovan R; Pennsylvania State University College of Medicine- Hershey Medical Center, Hershey, PA, USA., Eisen H; Pennsylvania State University College of Medicine- Hershey Medical Center, Hershey, PA, USA., Ali O; Pennsylvania State University College of Medicine- Hershey Medical Center, Hershey, PA, USA. oali@pennstatehealth.psu.edu. |
| المصدر: | Handbook of experimental pharmacology [Handb Exp Pharmacol] 2022; Vol. 272, pp. 39-52. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902231 Publication Model: Print Cited Medium: Print ISSN: 0171-2004 (Print) Linking ISSN: 01712004 NLM ISO Abbreviation: Handb Exp Pharmacol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin, New York, Springer-Verlag. |
| مواضيع طبية MeSH: | Graft Rejection* , Immunosuppressive Agents*/adverse effects, Humans ; Mycophenolic Acid/pharmacology ; Mycophenolic Acid/therapeutic use |
| مستخلص: | Antiproliferative agents include Mycophenolic acid and Azathioprine (which is less commonly used unless in certain conditions). They were initially identified for use in autoimmune and cancer research due to their role in disruption of cellular replication. They have now become the cornerstone of antirejection maintenance therapy in solid organ transplant. In this chapter we will describe the major times that lead to discovery, mechanisms of action, side effects, use during pregnancy and the major clinical trials. (© 2021. Springer Nature Switzerland AG.) |
| References: | A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group (1996) Transplantation 61(7):1029–1037. Aarbakke J, Janka-Schaub G, Elion GB (1997) Thiopurine biology and pharmacology. Trends Pharmacol Sci 18(1):3–7. (PMID: 10.1016/S0165-6147(96)01007-3) Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Rådegran G, Gude E et al (2016) Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients: three-year results from the randomized SCHEDULE study. Am J Transplant 16(4):1238–1247. https://doi.org/10.1111/ajt.13588. (PMID: 10.1111/ajt.1358826820618) Baran DA, Zucker MJ, Arroyo LH, Camacho M, Goldschmidt ME, Nicholls SJ et al (2011) A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial. Circ Heart Fail 4(2):129–137. https://doi.org/10.1161/CIRCHEARTFAILURE.110.958520. (PMID: 10.1161/CIRCHEARTFAILURE.110.95852021216835) Bechstein WO, Suzuki Y, Kawamura T, Jaffee B, Allison A, Hullett DA et al (1992) Low-dose combination therapy of DUP-785 and RS-61443 prolongs cardiac allograft survival in rats. Transpl Int 5(Suppl 1):S482–S483. (PMID: 10.1111/tri.1992.5.s1.482) Bentley R (2000) Mycophenolic acid: a one hundred year odyssey from antibiotic to immunosuppressant. Chem Rev 100(10):3801–3826. (PMID: 10.1021/cr990097b) Bunnapradist S, Ambühl PM (2008) Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies. Clin Transpl 22(6):815–821. https://doi.org/10.1111/j.1399-0012.2008.00892.x. (PMID: 10.1111/j.1399-0012.2008.00892.x) Byrne R, Yost SE, Kaplan B (2011) Mycophenolate mofetil monitoring: is there evidence that it can improve outcomes? Clin Pharmacol Ther 90(2):204–206. https://doi.org/10.1038/clpt.2011.95. (PMID: 10.1038/clpt.2011.9521772295) Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA et al (2003) Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349(9):847–858. https://doi.org/10.1056/NEJMoa022171. (PMID: 10.1056/NEJMoa02217112944570) Eisen HJ, Kobashigawa J, Starling RC, Pauly DF, Kfoury A, Ross H et al (2013) Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant 13(5):1203–1216. https://doi.org/10.1111/ajt.12181. (PMID: 10.1111/ajt.1218123433101) Elion GB (1989) The purine path to chemotherapy. Science 244(4900):41–47. (PMID: 10.1126/science.2649979) Elion GB, Callahan SW, Hitchings GH, Rundles RW (1960) The metabolism of 2-amino-6-[(1-methyl-4-nitro-5-imidazolyl)thio]purine (B.W. 57-323) in man. Cancer Chemother Rep 8:47–52. (PMID: 13849699) Ensley RD, Bristow MR, Olsen SL, Taylor DO, Hammond EH, O'Connell JB et al (1993) The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 56(1):75–82. (PMID: 10.1097/00007890-199307000-00013) Fischer L, Sterneck M, Gahlemann CG, Malago M, Rogiers X, Broelsch CE (2000) A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients. Transplant Proc 32(7):2125–2127. https://doi.org/10.1016/s0041-1345(00)01599-2. (PMID: 10.1016/s0041-1345(00)01599-211120098) Gonwa T, Mendez R, Yang HC, Weinstein S, Jensik S, Steinberg S et al (2003) Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation 75(8):1213–1220. https://doi.org/10.1097/01.TP.0000062837.99400.60. (PMID: 10.1097/01.TP.0000062837.99400.6012717205) Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C (1997) Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 63(1):39–47. (PMID: 10.1097/00007890-199701150-00008) Jain AB, Hamad I, Rakela J, Dodson F, Kramer D, Demetris J et al (1998) A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation 66(10):1395–1398. (PMID: 10.1097/00007890-199811270-00024) Jeong H, Kaplan B (2007) Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol 2(1):184–191. https://doi.org/10.2215/CJN.02860806. (PMID: 10.2215/CJN.0286080617699403) Ji Y, Gu J, Makhov AM, Griffith JD, Mitchell BS (2006) Regulation of the interaction of inosine monophosphate dehydrogenase with mycophenolic acid by GTP. J Biol Chem 281(1):206–212. https://doi.org/10.1074/jbc.M507056200. (PMID: 10.1074/jbc.M50705620016243838) Johnson C, Ahsan N, Gonwa T, Halloran P, Stegall M, Hardy M et al (2000) Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 69(5):834–841. (PMID: 10.1097/00007890-200003150-00028) Keogh A, Richardson M, Ruygrok P, Spratt P, Galbraith A, O'Driscoll G et al (2004) Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 110(17):2694–2700. https://doi.org/10.1161/01.CIR.0000136812.90177.94. (PMID: 10.1161/01.CIR.0000136812.90177.9415262845) Kim M, Rostas S, Gabardi S (2013) Mycophenolate fetal toxicity and risk evaluation and mitigation strategies. Am J Transplant 13(6):1383–1389. https://doi.org/10.1111/ajt.12238. (PMID: 10.1111/ajt.1223823617812) Klupp J, Glanemann M, Bechstein WO, Platz KP, Langrehr JM, Keck H et al (1999) Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. Transplant Proc 31(1–2):1113–1114. (PMID: 10.1016/S0041-1345(98)01925-3) Kobashigawa J (2017) Clinical trials in heart transplantation: the evolution of evidence in immunosuppression. J Heart Lung Transplant 36(12):1286–1290. https://doi.org/10.1016/j.healun.2017.10.009. (PMID: 10.1016/j.healun.2017.10.00929173388) Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R et al (1998) A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 66(4):507–515. (PMID: 10.1097/00007890-199808270-00016) Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker MJ, Goldberg LR et al (2006) Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 6(6):1377–1386. https://doi.org/10.1111/j.1600-6143.2006.01290.x. (PMID: 10.1111/j.1600-6143.2006.01290.x16686761) Maltzman JS, Koretzky GA (2003) Azathioprine: old drug, new actions. J Clin Invest 111(8):1122–1124. https://doi.org/10.1172/JCI18384. (PMID: 10.1172/JCI1838412697731152947) McNeil K, Glanville AR, Wahlers T, Knoop C, Speich R, Mamelok RD et al (2006) Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation 81(7):998–1003. https://doi.org/10.1097/01.tp.0000202755.33883.61. (PMID: 10.1097/01.tp.0000202755.33883.6116612275) Merion RM, Henry ML, Melzer JS, Sollinger HW, Sutherland DE, Taylor RJ (2000) Randomized, prospective trial of mycophenolate mofetil versus azathioprine for prevention of acute renal allograft rejection after simultaneous kidney-pancreas transplantation. Transplantation 70(1):105–111. (PMID: 10919583) Murray JE, Merrill JP, Harrison JH, Wilson RE, Dammin GJ (1963) Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med 268:1315–1323. https://doi.org/10.1056/NEJM196306132682401. (PMID: 10.1056/NEJM19630613268240113936775) Natekar A, Pupco A, Bozzo P, Koren G (2011) Safety of azathioprine use during pregnancy. Can Fam Physician 57(12):1401–1402. (PMID: 221701923237512) Odorico JS, Pirsch JD, Knechtle SJ, D'Alessandro AM, Sollinger HW (1998) A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation. Transplantation 66(12):1751–1759. (PMID: 10.1097/00007890-199812270-00032) Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman AB, Cibrik D, Magee JC et al (2000) Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69(11):2405–2409. (PMID: 10.1097/00007890-200006150-00033) Ortega F, Sánchez-Fructuoso A, Cruzado JM, Gómez-Alamillo JC, Alarcón A, Pallardó L et al (2011) Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium. Transplantation 92(4):426–432. https://doi.org/10.1097/TP.0b013e31822527ca. (PMID: 10.1097/TP.0b013e31822527ca21760569) Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group (1995) Lancet 345(8961):1321–1325. Poppe D, Tiede I, Fritz G, Becker C, Bartsch B, Wirtz S et al (2006) Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 176(1):640–651. (PMID: 10.4049/jimmunol.176.1.640) Ransom JT (1995) Mechanism of action of mycophenolate mofetil. Ther Drug Monit 17(6):681–684. (PMID: 10.1097/00007691-199512000-00023) Regueira TB, Kildegaard KR, Hansen BG, Mortensen UH, Hertweck C, Nielsen J (2011) Molecular basis for mycophenolic acid biosynthesis in Penicillium brevicompactum. Appl Environ Microbiol 77(9):3035–3043. https://doi.org/10.1128/AEM.03015-10. (PMID: 10.1128/AEM.03015-10213984903126426) Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW et al (2013) Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther 93(4):324–325. https://doi.org/10.1038/clpt.2013.4. (PMID: 10.1038/clpt.2013.4234228733604643) Remuzzi G, Cravedi P, Costantini M, Lesti M, Ganeva M, Gherardi G et al (2007) Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol 18(6):1973–1985. https://doi.org/10.1681/ASN.2006101153. (PMID: 10.1681/ASN.200610115317460145) Salvadori M, Holzer H, de Mattos A, Sollinger H, Arns W, Oppenheimer F et al (2004) Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 4(2):231–236. (PMID: 10.1046/j.1600-6143.2003.00337.x) Schwartz R, Stack J, Dameshek W (1958) Effect of 6-mercaptopurine on antibody production. Proc Soc Exp Biol Med 99(1):164–167. (PMID: 10.3181/00379727-99-24281) Shapiro R, Jordan ML, Scantlebury VP, Vivas C, Marsh JW, McCauley J et al (1999) A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation 67(3):411–415. (PMID: 10.1097/00007890-199902150-00012) Sollinger HW (1995) Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60(3):225–232. (PMID: 10.1097/00007890-199508000-00003) Strueber M, Warnecke G, Fuge J, Simon AR, Zhang R, Welte T et al (2016) Everolimus versus mycophenolate mofetil de novo after lung transplantation: a prospective, randomized, open-label trial. Am J Transplant 16(11):3171–3180. https://doi.org/10.1111/ajt.13835. (PMID: 10.1111/ajt.1383527104933) Taylor DO, Ensley RD, Olsen SL, Dunn D, Renlund DG (1994) Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation. J Heart Lung Transplant 13(4):571–582. (PMID: 7947873) Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J et al (2001) A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 7(5):442–450. https://doi.org/10.1053/jlts.2001.23356. (PMID: 10.1053/jlts.2001.2335611349266) Zhang L, Demain AL (2005) Natural products: drug discovery and therapeutic medicine. Humana Press. (PMID: 10.1007/978-1-59259-976-9) |
| فهرسة مساهمة: | Keywords: Antiproliferatives; Azathioprine; Clinical trials; Discovery; Mechanism of action; Mycophenolic acid; Side effects |
| المشرفين على المادة: | 0 (Immunosuppressive Agents) HU9DX48N0T (Mycophenolic Acid) |
| تواريخ الأحداث: | Date Created: 20211026 Date Completed: 20220708 Latest Revision: 20220708 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1007/164_2021_556 |
| PMID: | 34697667 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0171-2004 |
|---|---|
| DOI: | 10.1007/164_2021_556 |